OSI Pharmaceuticals Inc. Sustainability Profile
OSI Pharmaceuticals Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1992, the company has established itself as a leader in the development of innovative therapies, particularly in oncology and diabetes management. With a strong focus on research and development, OSI Pharmaceuticals has achieved significant milestones, including the successful launch of targeted therapies that address unmet medical needs. The company’s core products, such as its flagship oncology drug, exemplify its commitment to advancing patient care through cutting-edge science. OSI Pharmaceuticals is recognised for its unique approach to drug development, leveraging advanced technologies to enhance treatment efficacy. With a solid market position and a reputation for excellence, OSI Pharmaceuticals continues to make strides in improving health outcomes globally.
DitchCarbon Score
How does OSI Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OSI Pharmaceuticals Inc.'s score of 23 is lower than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OSI Pharmaceuticals Inc.'s reported carbon emissions
OSI Pharmaceuticals Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges. This lack of emissions data and formal commitments suggests that OSI Pharmaceuticals may not yet be actively engaging in climate initiatives or reporting under frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As the pharmaceutical industry increasingly prioritises sustainability, OSI Pharmaceuticals may need to consider developing and communicating its climate commitments to align with industry standards and expectations.
How Carbon Intensive is OSI Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is OSI Pharmaceuticals Inc.'s Location?
OSI Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
OSI Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.